Setting new standards in information exchange for the pharmaceutical and biotech industry
Rational Combinations Supporting Partner, CRI launches Phase 1/2 trial of combination immunotherapy with Ludwig Cancer Research
April 7, 2016
Cancer Research Institute, a supporting partner of Rational Combinations 360°, together with Ludwig Cancer Research have launched a Phase 1/2 clinical trial of combination immunotherapy for advanced ovarian cancer.
The international, multicenter trial is led by George Coukos, director of the Ludwig Institute for Cancer Research, Lausanne and Brad Monk, director of Gynecologic Oncology at St. Joseph’s Hospital and Medical Center. The study is being conducted through the CVC Trials Network, which is jointly managed by Ludwig and CRI, in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, and the biopharmaceutical company VentiRx Pharmaceuticals Inc.
“Ludwig has long supported the design and evaluation of new therapeutic strategies to improve the treatment options available to cancer patients,” said Jonathan Skipper, Ludwig’s executive vice president of Technology Development. “Employing immunotherapies in combination holds great promise in that endeavor. We are proud to be a part of this effort to bring investigational drugs being developed by different commercial partners to a single clinical trial and improve the standard of care for recurrent ovarian cancer, a disease for which patients today have few treatment options.”
Continue Reading the Article here.
Rational Combinations 360° (June 23-24,2016 in NYC) is the only event addressing business aspects, novel clinical trial designs and scientific developments for combination immunotherapies. For more information on the program, click here.